Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Breast Cancer Research : BCR|October 6, 2010
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerIsabel F Pinhel, Fiona A Macneill, Margaret J Hills, et al.
Journal of the National Cancer Institute|March 23, 2011
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreementAlan Mackay, Britta Weigelt, Anita Grigoriadis, et al.
Clinical Sarcoma Research|May 20, 2015
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcomaBeatrice Seddon, Michelle Scurr, Robin L Jones, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 28, 2004
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemiaPatrick D Thornton, Alicja M Gruszka-Westwood, Rifat A Hamoudi, et al.
Breast Cancer Research : BCR|March 16, 2012
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancerIsabel Pinhel, Margaret Hills, Suzanne Drury, et al.
Cancer|October 8, 2005
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemiaIlaria Del Giudice, Alison Morilla, Nnenna Osuji, et al.
The New England Journal of Medicine|February 20, 2004
Excision margins in high-risk malignant melanomaJ Meirion Thomas, Julia Newton-Bishop, Roger A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?Desiree F Kolomainen, Roger A'Hern, Fareeda Y Coxon, et al.
Journal of Clinical Pathology|December 15, 2010
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancerRobin L Jones, Federico Rojo, Roger A'Hern, et al.
Breast Cancer Research and Treatment|March 16, 2012
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patientsRoberta Ferraldeschi, Monica Arnedos, Kristen D Hadfield, et al.
Pageof 8